English
Our history
A French specialty pharma story
An entrepreneurial journey from inspiration to innovation.
Juvisé Pharmaceuticals is a family-owned pharmaceutical company with over 15 years of experience
Inspiration
From LynaPharm to Juvisé Pharmaceuticals.
In 2002, Frédéric Mascha was a French entrepreneur with extensive pharmaceutical experience gained from several years as an Associate Principal at a leading strategy consulting firm, where he worked in both Europe and the United States.
He observed a growing trend of U.S. companies being created as “Specialty Pharma” to acquire mature drugs divested by major pharmaceutical companies that were looking to refocus on their pipelines or other therapeutic areas.
He seized the opportunity with his first acquisition, a psychiatric drug from Pfizer, to found LynaPharm, a pharmaceutical company specializing in neuropsychiatry, in joint venture with the Italian pharmaceutical group Sigma-Tau.
Later, LynaPharm acquired the rights to two additional psychiatric drugs from Novartis and Astellas before being acquired by the Sigma-Tau group in 2008.
Inception and industry innovation
Juvise Pharmaceuticals: a European specialty pharma company.
After the success of LynaPharm, Frédéric Mascha funded Juvisé Pharmaceuticals in 2008.
In over 16 years, Juvisé Pharmaceuticals has grown and developed, acquiring princeps drugs in new therapeutic areas, from neuropsychiatry and cardiology to oncology, gastroenterology and neurology.
Juvisé Pharmaceuticals’ objective remains to identify and then acquire drugs recognized by the medical community for their therapeutic value. Once secured, we ensure their manufacturing, distribution, and marketing, making them available to 2.5 million patients each year.
Our ambition is to keep protecting patients’ health by providing them access to effective treatments that significantly improve their disease condition.
To this end, over the next few years, we will focus on becoming the preferred European commercial partner for research and major pharmaceutical companies worldwide.
Our History at a glance
Frédéric MASCHA creates Juvisé Pharmaceuticals
Frédéric MASCHA creates Juvisé Pharmaceuticals
Acquisition
Juvisé Pharmaceuticals acquires Lumirelax® (Thera France) and Extovyl® (Thera France)
Acquisition
Juvisé Pharmaceuticals acquires Lumirelax® (Thera France) and Extovyl® (Thera France)
Acquisition
Juvisé Pharmaceuticals acquires Entumin® (Novartis), Insidon® (Thera France) and Calmixène® (Thera France)
Acquisition
Juvisé Pharmaceuticals acquires Entumin® (Novartis), Insidon® (Thera France) and Calmixène® (Thera France)
Licensing
Juvisé Pharmaceuticals takes in license Proxeed Plus® (Sigma-Tau), Ezerex® (Sigma-Tau)
Licensing
Juvisé Pharmaceuticals takes in license Proxeed Plus® (Sigma-Tau), Ezerex® (Sigma-Tau)
Acquisition
Juvisé Pharmaceuticals acquires Esidrex® (Novartis), Sintrom® (Novartis) and Digoxine-Juvisé® (Novartis)
Acquisition
Juvisé Pharmaceuticals acquires Esidrex® (Novartis), Sintrom® (Novartis) and Digoxine-Juvisé® (Novartis)
Acquisition
Juvisé Pharmaceuticals acquires Arimidex® (AstraZeneca) and Casodex® (AstraZeneca)
Acquisition
Juvisé Pharmaceuticals acquires Arimidex® (AstraZeneca) and Casodex® (AstraZeneca)
January 1, 2020: Senegal grants marketing authorisation for Lumirelax® (methocarbamol) for the adjunctive treatment of painful muscular contractures in rheumatology.
January 1, 2020: Senegal grants marketing authorisation for Lumirelax® (methocarbamol) for the adjunctive treatment of painful muscular contractures in rheumatology.
February 1, 2022: Albania grants marketing authorisation for Esidrex® (hydrochlorothiazide) for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, usually in combination with a potassium-sparing diuretic, and for the treatment of arterial hypertension.
February 1, 2022: Albania grants marketing authorisation for Esidrex® (hydrochlorothiazide) for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, usually in combination with a potassium-sparing diuretic, and for the treatment of arterial hypertension.
Acquisition
Juvisé Pharmaceuticals acquires Pylera® (Abbvie)
Acquisition
Juvisé Pharmaceuticals acquires Pylera® (Abbvie)
September 18, 2023: Morocco grants marketing authorisation for Lumirelax® (methocarbamol) for the adjunctive treatment of painful muscular contractures in rheumatology.
September 18, 2023: Morocco grants marketing authorisation for Lumirelax® (methocarbamol) for the adjunctive treatment of painful muscular contractures in rheumatology.
December 29, 2023: Mali grants marketing authorisation for Sintrom® (acenocoumarol) in the treatment of oedema due to heart or renal disease, oedema due to hepatic impairment, usually in combination with a potassium-sparing diuretic, and in the treatment of arterial hypertension.
December 29, 2023: Mali grants marketing authorisation for Sintrom® (acenocoumarol) in the treatment of oedema due to heart or renal disease, oedema due to hepatic impairment, usually in combination with a potassium-sparing diuretic, and in the treatment of arterial hypertension.
March 1, 2024: The MHRA grants marketing authorization for Pylera® in the UK for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers, in combination with omeprazole, in patients with active or a history of H. pylori associated ulcers.
March 1, 2024: The MHRA grants marketing authorization for Pylera® in the UK for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers, in combination with omeprazole, in patients with active or a history of H. pylori associated ulcers.
Acquisition
Juvisé Pharmaceuticals acquires global commercial rights (excluding the United States and Canada) to Ponvory® (Johnson & Johnson Innovative Medicine) indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS).
Acquisition
Juvisé Pharmaceuticals acquires global commercial rights (excluding the United States and Canada) to Ponvory® (Johnson & Johnson Innovative Medicine) indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS).
December 7, 2024: Vietnam grants marketing authorisation for Sintrom® (acenocoumarol) in the treatment and prevention of thromboembolic disorders.
December 7, 2024: Vietnam grants marketing authorisation for Sintrom® (acenocoumarol) in the treatment and prevention of thromboembolic disorders.
JUV-FRA-202408-0213, 09/2024
More about Juvisé Pharmaceuticals
From neuroscience to gastroenterology, our medications treat 2.5 million patients each year
Join Juvisé Pharmaceuticals and become part of a company that values excellence and commitment
From neuroscience to gastroenterology, our medications treat 2.5 million patients each year
Join Juvisé Pharmaceuticals and become part of a company that values excellence and commitment